TAK-919 is Takeda's development code for Moderna's COVID-19 vaccine candidate.
Takeda is conducting a placebo-controlled Phase 1/2 study designed to evaluate the safety and immunogenicity of two vaccinations of mRNA-1273 at the 100 μg dose level given 28 days apart in 200 participants aged 20 years and above in Japan.
Participants will be followed through 12 months after the second vaccination. The ClinicalTrials.gov identifier is NCT04677660.
Takeda completed enrollment of this Phase 1/2 study in February, 2021. Once available, the Phase 1/2 study results will be submitted to the Japan Pharmaceuticals and Medical Devices Agency.
Takeda and Moderna previously announced that Takeda will import and distribute 50 m doses of Moderna's COVID-19 vaccine candidate starting in the first half of 2021, pending licensure in Japan.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100